Diagnostic features, treatment, and outcome of dogs with inflammatory protein‐losing enteropathy by Salavati, Silke et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diagnostic features, treatment, and outcome of dogs with
inflammatory proteinlosing enteropathy
Citation for published version:
Salavati, S, Gow, A, Bommer, N, Morrison, L & Mellanby, R 2019, 'Diagnostic features, treatment, and
outcome of dogs with inflammatory proteinlosing enteropathy', Journal of Veterinary Internal Medicine.
https://doi.org/10.1111/jvim.15571
Digital Object Identifier (DOI):
10.1111/jvim.15571
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Journal of Veterinary Internal Medicine
Publisher Rights Statement:
This is an open access article under the terms of the Creative Commons AttributionNonCommercial License,
which permits use, distribution and reproduction in any medium, provided the original work is properly cited and
is not used for commercial purposes.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 11. May. 2020
S T ANDA RD AR T I C L E
Diagnostic features, treatment, and outcome of dogs with
inflammatory protein-losing enteropathy
Silke Salavati Schmitz1 | Adam Gow1 | Nick Bommer1 | Linda Morrison2 |
Richard Mellanby1
1University of Edinburgh, The Royal (Dick)
School of Veterinary Studies and The Roslin
Institute, Hospital for Small Animals,
Midlothian, United Kingdom
2University of Edinburgh, The Royal (Dick)
School of Veterinary Studies and The Roslin
Institute, Easter Bush Pathology, Midlothian,
United Kingdom
Correspondence
Silke Salavati Schmitz, University of Edinburgh,
The Royal (Dick) School of Veterinary Studies,
Hospital for Small Animals, Easter Bush,
Midlothian, United Kingdom.
Email: silke.salavati@ed.ac.uk
Abstract
Background: Protein-losing enteropathy (PLE) because of chronic inflammatory
enteropathy (CIE) in dogs is often treated with a combination of glucocorticoids and
second-line immunosuppressant (SLI). This combined approach might not be necessary in
all dogs.
Hypothesis/objectives: To describe diagnostic features and outcomes of dogs with PLE
treated with glucocorticoids alone (group P) or with glucocorticoids and SLI (group S).
Animals: Thirty-one dogs with PLE.
Material and methods: Retrospective analysis of signalment data from diagnostic
procedures, treatment, and outcome of dogs with CIE/PLE (from 2015 to 2017),
using the hospital's digital case database. Dogs with hypoalbuminemia and CIE were
included. Because of a stepwise treatment algorithm, dogs were allocated to group P
or S. Time to serum albumin concentrations ≥20 g/L and survival data were collected.
Dogs were additionally categorized by their albumin and cobalamin serum concentra-
tions. Multivariate and univariate analysis as well as Pearson's correlation and
Kaplan-Maier survival analysis were performed.
Results: Seventeen dogs were included in group P and 14 in group S. World Small
Animal Veterinary Association score of the duodenum was different between groups
(P = .05), but none of the other examined data. Median time until serum albumin
reached >20 g/L was 13 days. Median survival time after start of treatment was
85 days (range, 13-463 days) in group P and 166 days (range, 8-390 days) in group S.
Conclusion and Clinical Importance: No routine diagnostic test was predictive of
clinical response, treatment group, or outcome. Glucocorticoid treatment alone can
be appropriate in dogs with PLE.
K E YWORD S
chronic enteropathy, cobalamin, hypoalbuminemia, inflammatory bowel disease, prognosis
1 | INTRODUCTION
Protein-losing enteropathy (PLE) is a syndrome characterized by
excessive loss of serum albumin across the intestinal wall.1-3 Many
Abbreviations: CCECAI, Canine Chronic Enteropathy Clinical Activity Index; CIBDAI, Canine
Inflammatory Bowel Disease Activity Index; CIE, chronic inflammatory enteropathy;
MANOVA, multivariate analysis of variance; PLE, protein-losing enteropathy; SLI, second-line
immunosuppressive drug; WSAVA, World Small Animal Veterinary Association.
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different dog breeds can be affected, with some at increased risk.1,4-6
Underlying causes vary and include primary (congenital) and secondary
(acquired) lymphangiectasia, chronic inflammatory enteropathies (CIE),
most commonly lymphoplasmacytic enteritis, intestinal neoplasia (princi-
pally alimentary lymphoma), and infectious disease.3 Even though hypo-
albuminemia is the hallmark of PLE, additional laboratory abnormalities
occur, including lymphopenia, hypocholesterolemia, hypoglobulinemia,
hypocalcemia, and hypomagnesemia.2,3 The severity of clinical signs
(often assessed by the canine IBD activity index [CIBDAI]7 or the canine
chronic enteropathy clinical activity index [CCECAI]8), serum albumin
concentration (<20 g/L [2.0 g/dL]), and hypocobalaminemia are negative
prognostic indicators.2,3,8,9 Even though hypocobalaminemia is common
in dogs with PLE, and serum concentrations of cobalamin and albumin
correlate,8 the prevalence of hypocobalaminemia in dogs with PLE
because of CIE has not been described. Other negative prognostic indi-
cators include clinical abnormalities such as chronic vomiting,10 low
body weight,1,11,12 failure to normalize CIBDAI or CCECAI,13 laboratory
abnormalities (eg, decreased10 or increased12,13 blood urea nitrogen
concentration), high endoscopic scores, and duodenal inflammation.8
Elevations in serum C-reactive protein concentration and decreases
in 25(OH) vitamin D serum concentration also have prognostic
value.11,14,15
In cases of PLE, abdominal ultrasonography identifies intestinal
lesions, concurrent lymphadenopathy and allows better distinction
between inflammatory and neoplastic causes.2,3 Hyperechoic mucosal
stippling or striations are associated with lacteal dilation, having a sen-
sitivity of 75% and a specificity of 96% for PLE.16,17 However, diag-
nostic imaging findings have not been evaluated for their prognostic
value. Endoscopy and histopathology scores are inconsistent predic-
tors of diagnosis and prognosis of PLE.8,15,17
Given survival rates of dogs with PLE of 30%-40%,3,15 most treat-
ment protocols involve an aggressive and multimodal approach, com-
bining dietary modification, administration of antimicrobials, and
immunosuppressive drugs. Recently, immunosuppressive treatment
in PLE has come under some scrutiny because of adverse effects of
glucocorticoid treatment and an encouraging clinical response to
various dietary interventions alone, for example, in Yorkshire Ter-
riers with PLE.10,15 Also, immunosuppressive treatment is signifi-
cantly associated with a negative outcome compared with dietary
management of PLE.15 However, most of the studies demonstrating
a beneficial effect of diet alone are restricted to PLE occurring in a
single breed (mostly Yorkshire Terriers), so it is unknown if these
dogs have a dietary-responsive phenotype of the disease or if this
treatment could also be applied to a wider population of dogs with
PLE. The idea that steroids should be combined with a second-line immu-
nosuppressant (SLI) is based on a study investigating risk factors for a neg-
ative outcome in CIE, in which none of the 10 dogs with PLE responded
to glucocorticoid treatment alone.8 Subsequent addition of cyclosporine
rescued 7 of 10 dogs from euthanasia.8 Treatment with prednisolone
alone, the combinations of prednisolone and azathioprine, cyclosporine, or
methotrexate are all described.1,8,18 Increasingly, mycophenolate mofetil is
also empirically used, and in some refractory cases more than 1 SLI is pre-
scribed. A chlorambucil-prednisolone combination for treatment of CIE
with concurrent PLE resulted in significantly improved serum albumin con-
centration and weight gain compared to treatment with an azathioprine-
prednisolone combination.1 Median survival time was not reached for the
chlorambucil-prednisolone treated dogs.1 However, no comparison of
chlorambucil with cyclosporine as a treatment for PLE has been published.
The percentage of dogs with PLE/CIE needing a SLI or if this can be asso-
ciated with any routinely obtained clinicopathological, diagnostic imaging,
endoscopic, or histological test is unknown.
The aim of the present study was to retrospectively determine the
proportion of dogs treated with glucocorticoids for inflammatory PLE
that respond to this treatment alone (without the subsequent require-
ment for an SLI) and to describe data from history, laboratory evalua-
tions, ultrasound, endoscopy, histology, and clinical outcome. Routine
diagnostic tests were assessed for their potential association with
treatment requirements, prognosis, or outcome.
2 | MATERIALS AND METHODS
Retrospective case acquisition was performed by using the electronic
client data management system's (Tristan Veterinary Software Ltd, ver-
sion 1.8.3.914, Orion Engineering Services, Orion House, Inverness,
United Kingdom) search tool. Search terms used within both the free
text clinical record as well as VeNom (veterinary nomenclature) diagnos-
tic code were “protein losing enteropathy,” “cobalamin,” “inflammatory
bowel disease,” “(chronic) enteropathy,” “food intolerance,” and “hypo-
albuminemia.” The search was conducted for a time frame spanning
from January 1, 2015, to December 31, 2017. Search results were
exported into commercial software (Microsoft Excel spreadsheet soft-
ware, Microsoft Corporation, Redmond, Washington). Duplicate files
were removed manually. Only first visits of dogs were included. Of the
remaining files, the first serum albumin concentration on record as well
as the final diagnosis was revisited by 1 of the authors (S.S.S.). Dogs with
a serum albumin concentration within the reference range (26-35 g/L)
were excluded. Files of dogs with acute disease, intestinal neoplasia, GI
bleeding, concurrent diseases not allowing the accurate diagnosis of
PLE, and dogs without a final diagnosis were excluded. Of the remaining
dogs, available data from history, physical examination, clinicopathologi-
cal values, endoscopy (including scores as previously reported19), histo-
pathology, treatment, and outcome were collated. Because a stepwise
treatment algorithm for dogs with PLE was in place (Supporting Infor-
mation Figure S1), dogs could be allocated to 1 of 2 treatment groups:
group P consisted of dogs that had received supportive treatment, die-
tary management and glucocorticoids (prednisolone), but no SLI; and
group S, which consisted of dogs that had received similar treatments
but the addition of a SLI. For both groups, time to reach a serum albu-
min ≥20 g/L (identified as an acceptable short-term treatment target) as
well as survival data was collected. Dogs were additionally categorized
by their albumin and cobalamin serum concentrations, respectively, to
allow assessment of potential impact of these data on outcome. Deter-
mination of serum cobalamin concentrations was done in the same com-
mercial laboratory (IDEXX Laboratories Ltd, Wetherby, West Yorkshire,
United Kingdom; for all dogs apart from 1) with a reference range of
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>250 ng/mL and a lower detection limit of the assay of <150 ng/mL,
hence categories were chosen to represent severe hypocobalaminemia
(<150 ng/mL), moderate hypocobalaminemia (150-250 ng/mL) and nor-
mal serum cobalamin concentrations (>250 ng/mL).
Ultrasound findings were assessed based on the initial diagnostic
report (by board-certified or board-eligible diagnostic imagers); images
were not reviewed specifically for the purpose of this study. Gastroin-
testinal abnormalities recorded were categorized by section of the GI
tract (stomach, small intestine, large intestine) and into the presence
or absence of 1 or more of the following: mucosal lesions (specifically
hyperechogenicity, hyperechoic striations, and speckles), changes of
the entire wall or loss of layering, subjective dysmotility or ileus, as
well as abnormalities of intra-abdominal lymph nodes and presence of
free peritoneal fluid.
Endoscopy scores were available from initial reports issued by the
board-certified or board-eligible specialist in small animal internal medi-
cine performing the endoscopy. For this, the grading system proposed
by the World Small Animal Veterinary Association (WSAVA) Interna-
tional Gastrointestinal Standardization Group was used.20 Briefly, each
segment of the GI tract is evaluated for the absence/ presence and
severity of a given list of lesions, which can each be graded as normal
(=0), mild (=1), moderate (=2), or severe (=3). Maximum achievable
scores based on this system are 30 for stomach and duodenum, 27 for
the ileum, and 21 for the colon. Sums of these scores by GI segment
were used for analysis in this study.
Histopathological diagnosis was based on the initial case file informa-
tion, however, for the purpose of this study, all slides were reexamined
(or recut if not considered adequate) and scored according to WSAVA
guidelines21 by a single board-certified pathologist (LM).
2.1 | Statistical analysis
Normality of data was assessed using Shapiro-Wilk test. For multivariate
analysis of variance (MANOVA), missingness of data was imputed by
median replacement before postprocessing, but not used for univariate
downstream analysis. Multivariate analysis of variance (general linear
model) was performed separately for treatment group (P or S), survival
status (deceased or alive) and cobalamin status (>250 ng/mL, between
150 and 250 ng/mL, <150 ng/mL) as fixed factors. Interactions between
variables were also examined using this model. Least significant differ-
ence was used as a post hoc test where appropriate. Student's t tests or
Mann-Whitney U tests were used for univariate comparison of selected
data between treatment groups and for survival status. Tukey's correc-
tion was used to adjust for multiple comparisons. Pearson's correlation
analysis of clinicopathological and histologic scores with treatment status
and outcome was also performed (for correlation analysis with cobalamin
values, concentrations reported as <150 ng/mL were set to 149 ng/mL).
A Kaplan-Maier diagram was used for survival analysis comparing group
P and S (Log rank test). All statistical tests were conducted and graphs
created using commercially available statistical software (IBM SPSS Sta-
tistics, version 22, IBM Corporation, New York, New York; GraphPad
Prism, version 8.0.2, GraphPad Software Inc, San Diego, California); and
P < .05 was considered significant.
3 | RESULTS
Retrospective database search yielded 298 “hits” for the used search terms.
After removal of duplicates, 244 cases remained. Cases initially excluded
were: n = 13 revisits, n = 5 serum albumin concentration not recorded,
n = 1 diagnosed with Immerslund-Gräsbeck syndrome. Of the remaining
225 dogs, 63 were hypoalbuminemic. Of these, n = 11 were excluded as
they had a final diagnosis not consistent with inflammatory PLE (lymphoma
n = 3, intestinal intussusception n = 3, intestinal adenocarcinoma n = 2,
granulomatous colitis n = 2, and low albumin because of vegan diet n = 1).
A further 9 were excluded as no final diagnosis was reached. Five hypoal-
buminemic dogs were excluded because of concurrent diseases interfering
with the diagnosis of PLE (n = 1 of each of the following: diabetes mellitus,
protein-losing nephropathy,multiple endocrinopathies and IMHA, exocrine
pancreatic insufficiency, bilateral adrenal masses with vascular invasion,
and an aortic thrombus). Four dogswere excluded because of suspected or
proven intestinal blood loss or iron deficiency (based on serum iron panel)
and a single dogwas excluded as the low serum albumin concentrationwas
a clerical error (the dog was eventually diagnosed with food-responsive
enteropathy). This left a final number of 33 dogs with PLE because of CIE.
Signalment, history, diagnostic procedures performed, andmain findings of
these 33 dogs can be found in Table S1.
Thirty-one out of 33 dogs followed the hospital's diagnostic and
treatment protocol: 17 dogs (55%) in group P and 14 dogs (45%) in
group S. The remaining 2 dogs were mildly hypoalbuminemic and
treated with diet and tylosin only and therefore not included in further
analyses. Thirteen of the 14 dogs in group S received cyclosporine as
SLI and the remaining dog received chlorambucil. The mean serum albu-
min concentration of all dogs at time of first presentation was 19.4 g/L
(SD, 4.5), the mean of the lowest serum albumin concentration recorded
was 16.8 g/L (SD, 4.4). Additional biochemical abnormalities included:
hypoglobulinemia (15/31), hypocholesterolemia (21/31), total hypocal-
cemia (31/31), ionized hypocalcemia (4/25), and total hypomagnesemia
(17/31). Hypocobalaminemia was present in 19/31 dogs (61%) with
8 of those 19 dogs showing cobalamin values lower than the measuring
threshold of the laboratory (GraphPad Software Inc; <150 μmoL/L).
Folate was below the reference range in 12/29 dogs (41%), above it in
4/29 (14%), and within the reference range in the remaining dogs in
which it was measured.
Thirty dogs had a full abdominal ultrasound performed. The remaining
dog had a point-of-care ultrasound performed that revealed marked asci-
tes, followed by an abdominal CT. Lesions found on ultrasound included
abnormalities of the small intestine (n = 27/30), large intestine
(n = 13/30), abdominal lymph nodes (n = 12/30, described as reactive
changes, local, or diffuse mild to marked lymphadenomegaly), excessive
peritoneal fluid (n = 23/31), and dysmotility/intestinal ileus (n = 7/30). Spe-
cific abnormalities of the small intestines reported were generalized muco-
sal lesions (n = 14/30, described as hyperechoic striations and speckles,
hyperechoic mucosa, or enteritis), generalized lesions beyond the mucosa
(n = 8/30, described as diffusely thickened or thickening of the muscularis
layer). Jejunal ulcers were found in 2 cases. Colitis was described in 3 dogs
and nonobstructive foreign bodies were found in 2 dogs.
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Gastroduodenoscopy and colonoscopy with mucosal pinch
biopsies was performed in all dogs. Ileoscopy was performed in
21/31 dogs. Endoscopic scores were available for the stomach,
duodenum, and colon from 27/31 dogs and for the ileum from
19/21 dogs (Table S2). Overall, median endoscopic severity was
1 (range, 0-9) for the stomach, 7 (range, 0-20) for the duodenum,
0 (range, 0-10) for the colon, and 6 (range, 0-19) for the ileum,
respectively.
TABLE 1 Comparison of selected parameters between dogs with protein-losing enteropathy (PLE) treated with (group S, n = 14) and without
(group P, n = 17) a second-line immunosuppressive drug in addition to glucocorticoids
Variable tested
Group P median (range) or
mean (SD)
Group S median (range) or
mean (SD)
Significance level (P-
value)
Age (years)a 7.7 (1.7-11) 6.3 (2.5-12.6) .04
Serum albumin at presentation (g/L)b 19.1 (4.6) 19.7 (4.6) .69
Lowest recorded serum albumin (g/L)b 17.1 (4.1)b 16.5 (5.0) .70
Serum globulin (g/L)b 19.7 (5.6)b 19.3 (6.5) .86
Total protein (g/L)b 38.8 (8.5)b 39.1 (10.3) .94
Serum cholesterol (mmol/L)a 2.8 (1.6-8.3) 2.5 (1.7-4.7) .25
Total calcium (mmol/L)a 2.0 (1.1-2.3) 2.0 (0.7-2.3) .82
Ionized calcium (mmol/L)a 1.2 (0.8-1.4) 1.3 (0.6-1.4) .69
Total magnesium (mmol/L)b 0.7 (0.2) 0.6 (0.2) .29
BUN/urea (mmol/L)b 5.3 (2.7) 5.2 (2.1) .89
WBC (×10e9/L)b 11.5 (6.5) 13.4 (8.2) .90
Lymphocytes (×10e9/L)b 1.3 (1.0) 1.1 (0.6) .49
PCV (L/L)b 0.4 (0.1) 0.4 (0.1) .63
Platelets (10e9/L)b 433 (199) 399 (152) .60
Reticulocytes (10e9/L)b 52.8 (33.9) 100.0 (75.3) .11
Serum folate (μg/L)a 8.0 (2.1-18.7) 10.0 (4.2-22.5) .11
Serum cobalamin (ng/L)a 204 (<150-676) 183 (<150-1489) .72
Cortisol (nmol/L)a 88 (36.1-315) 74 (37-241) .68
Intestinal mucosal lesions on ultrasoundb 1.5 (0.5) 1.5 (0.5) .72
Intestinal full thickness lesions on
ultrasoundb
1.7 (0.5) 1.7 (0.5) .94
Lymphadenopathy on ultrasoundb 1.6 (0.5) 1.5 (0.5) .33
Free fluid on ultrasoundb 1.3 (0.5) 1.2 (0.4) .62
Abnormal stomach on ultrasoundb 1.7 (0.5) 1.8 (0.4) .71
Abnormal small intestine on ultrasoundb 1.1 (0.2) 1.2 (0.4) .44
Abnormal large intestine on ultrasoundb 1.7 (0.5) 1.4 (0.5) .09
Dysmotility/ ileus on ultrasoundb 1.6 (0.5) 1.9 (0.3) .06
Gastric endoscopy scorea 1.5 (0-9) 1.0 (0-7) .76
Duodenal endoscopy scoreb 7.1 (5.6) 7.1 (4.8) .97
Ileal endoscopy scoreb 6.0 (5.3) 4.5 (4.1) .28
Colonic endoscopy scorea 1.0 (0–10) 0 (0-6) .71
WSAVA histology score stomacha 2.0 (0-12) 2.0 (0-4) .74
WSAVA histology score duodenumb 7.1 (3.2) 4.8 (3.1) .05
WSAVA histology score ileumb 6.8 (3.9) 7.3 (3.4) .72
WSAVA histology score colona 2.0 (0-6) 2.5 (0-10) .52
WSAVA histology score totalb 12.2 (4.1) 9.6 (4.1) .09
Time to reach serum albumin >20 g/L (d)a 7 (0–33) 14 (0-77) .71
Survival time after diagnosis (d)a 85 (13-463) 166 (8-390) .39
Abbreviations: BUN, blood urea nitrogen; WBC, white blood cell; WSAVA, World Small Animal Veterinary Association.
aData not normally distributed.
bData of normal distribution.
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Histological diagnoses are summarized in Table S3: most frequent
findings were lymphoplasmacytic gastritis (n = 17/31) and colitis
(n = 17/31), whereas in the duodenum and ileum, lymphoplasmacytic plus
eosinophilic inflammation was most common (n = 10 for both locations,
respectively), followed by “chronic-active” lymphoplasmacytic plus neu-
trophilic inflammation (n = 9 duodenum, n = 7 ileum). Crypt abscessation
or dilation was found in 17/31, villous blunting in 14/31, and lacteal
dilation in 10/31 cases, respectively. Median WSAVA histology scores
(Table S2) for the stomach, duodenum, ileum, and colon were 2 (range,
0-12), 6 (range, 1-13), 7 (range, 0-15) and 2 (range, 0-10), respectively,
resulting in a median total score (omitting ileal scores, as they were not
available for all dogs) of 2 (range, 0-10).
Multivariate analysis of variance between group P and S highlighted
significant or borderline significant differences for initial serum albumin
(P = .05), total protein (P = .007), cholesterol (P = .04), white blood cell
count (WBC, P = .05), folate (P < .0001), cobalamin (P = .01), endoscopy
score of the duodenum (P = .007), and WSAVA histology score of the
ileum (P = .03) and colon (P = .04) (Table 1 and Figures 1 and 2). How-
ever, for pairwise/univariate comparisons (Table 1), only the WSAVA
histology score of the duodenum was significantly higher (P = .05) in
group P (mean, 7.12; SD, 3.19) than in group S (mean, 4.79; SD, 3.09).
There were no differences in MANOVA or univariate comparisons of
those same data between dogs that survived and those that died
(Figure 3). When dogs were grouped by cobalamin status, analysis of
variance revealed significant differences for total protein (P = .01), WBC
(P = .05), folate (P < .0001), endoscopy score of the duodenum (P = .01),
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F IGURE 1 Selected clinicopathological data from 31 dogs with
protein-losing enteropathy (PLE) treated with prednisolone alone
(group P) or with prednisolone and a second-line immunosuppressant
(group S): A, Serum albumin concentration at presentation; B, lowest
recorded serum albumin concentration; C, ionized calcium
concentration; D, serum folate concentration; E, serum cobalamin
concentration; and F survival time. For albumin, data are presented as
mean (horizontal bar) and SD (whiskers). All other data are presented
as median and interquartile range (whiskers)
F IGURE 2 World Small Animal Veterinary Association (WSAVA)
histology scores14 (A, stomach; B, duodenum; C, ileum; and D, colon)
from 31 dogs with protein-losing enteropathy (PLE) treated with
prednisolone alone (group P) or with prednisolone and a second-line
immunosuppressant (group S). A and D present data as median
(horizontal bar) and interquartile range (whiskers). B and C present
data as mean (horizontal bar) and SD (whiskers)
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and WSAVA score of the duodenum (P = .05), and ileum (P = .04), with
only folate remaining significantly different on post hoc analysis
(Figure 4). Folate was significantly lower in normocobalaminemic
dogs compared to mildly (P = .04) or severely hypocobalaminemic
dogs (P = .01), but not between mildly and severely hypo-
cobalaminemic dogs. Also, no differences in time to normalization of
serum albumin (Figure 5) or outcome could be detected across different
cobalamin status. Detailed P-values for comparisons of all data from dif-
ferent data groupings are summarized in Table S4. The relationship
between serum folate and cobalamin values was confirmed by an inverse
correlation (Figure 6). Strong positive pairwise correlations were also
detected among serum albumin concentration, serum globulin concen-
tration, serum total protein concentration, serum cholesterol concentra-
tion, total calcium concentration, and ionized calcium concentration,
respectively. In addition, total serum magnesium concentration corre-
lated positively with serum cholesterol concentration (P = .02; r = 0.427),
total calcium concentration (P = .009; r = 0.460), and ionized calcium
concentration (P < .0001; r = 0.909). Duodenal endoscopic score corre-
lated with serum albumin concentration (P = .022; r = − 0.438), serum
globulin concentration (P = .002; r = −0.567), serum total protein con-
centration (P = .002; r = −0.569), serum cholesterol concentration
(P = .04; r = −0.403), total calcium concentration (P = .01; r = −0.475),
and ionized calcium concentration (P = .04; r = −0.442), whereas ileal
endoscopic score only correlated with lowest (not initial) serum albumin
concentration (P = .02; r = −0.513), serum globulin concentration
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(P = .01; r = −0.558), and serum total protein concentration (P = .01;
r = −0.567). When assessing WSAVA histology scores, correlation was
observed between duodenal histology scores and duodenal endoscopy
scores (P = .02; r = 0.431). There was no correlation of any of the exam-
ined values with time to normalization of serum albumin concentration
or survival time.
Overall median time until the serum albumin concentration reached
>20 g/L was 13 days (range, 0-77 days), which was not significantly dif-
ferent between groups P and S (P = .71; Table 1). Median overall
follow-up was 99 days (range, 4-463 days). Eight dogs were deceased
by the end of the study (26%), 3 of which were in treatment group P
and 5 in group S (P = .28). Median survival was 85 days in group P and
166 days in group S (Figure 7), which was not significantly different
(P = .35; Table 1).
4 | DISCUSSION
Results of this study challenge the practice of immunosuppressive treat-
ment in addition to administration of glucocorticoids in dogs with PLE,8
even though the judgment of steroid responsiveness was not consis-
tently or objectively defined because of the retrospective nature of this
study. It also challenges the use of commonly determined clinicopatho-
logical values to predict outcome in these dogs. Especially severity of
hypoalbuminemia (neither at initial presentation to the referral center or
the lowest recorded value) and the presence of hypocobalaminemia did
not correlate with time to reach an “acceptable” serum albumin (which
was chosen to be >20 g/L for the purpose of this study) or overall out-
come, even though these values are reported to be negative prognostic
indicators.1-3,8-10,12,13 Based on the current findings, it might be justified
to attempt treatment with prednisolone first and to assess response to
treatment before adding a SLI, instead of the commonly used and advo-
cated “step-down approach” of immunosuppressive treatment (usually
glucocorticoids combined with cyclosporine, azathioprine, chlorambucil,
mycophelonate mofetil, or others) with the aim to slowly withdraw
treatment once an acceptable response or “remission” is achieved.
Ultrasonographic findings did not correlate with the severity of
hypoproteinemia or severity of disease, and hence were not associated
with treatment requirements or outcome in this study. Mucosal abnor-
malities previously associated with PLE were present in 47% of cases,
even though hyperechoic speckles and striations are reported to have a
sensitivity of 75% and specificity of 96% for PLE, repectively.17 How-
ever, reevaluation of ultrasound findings with a standardized scoring
system as used in other studies was not performed. One study has
questioned the diagnostic usefulness of abdominal ultrasound in dogs
with chronic diarrhea overall.22 However, this study was no specific to
PLE and omits the usefulness of being able to exclude certain (often
sinister) differential diagnoses in dogs with chronic diarrhea (eg, lymph-
adenopathy, solitary intestinal masses, chronic obstructions, and so
forth).
The inverse correlation of cobalamin and folate has not been
reported in dogs with CE or PLE before although serum folate levels
rise in 20%-30% of people with cobalamin deficiency.23,24 Hypo-
folatemia is a result of chronic malabsorption, but not specific for CIE
or PLE. Equally, normofolatemia does not exclude a diagnosis of CIE
or PLE.11 Medical consequences of folate deficiency are difficult to
predict, as neither serum folate concentrations nor serum cobalamin
concentrations were associated with treatment or outcome in the
population of dogs examined here. It is equally difficult to extrapolate
the clinical relevance of serum folate concentrations above the refer-
ence range (which was only present in 4 out of the 31 dogs). For
example, among people with cobalamin deficiency, patients with neu-
rological defects have higher mean concentrations of serum folate,24
but neuropathies are not frequently reported in dogs with acquired
cobalamin deficiency. In addition, there are limited to no similarities
between hematological abnormalities often observed with cobalamin
deficiency in people and dogs.25 Hyperfolatemia or “falsely normal”
serum folate values in dogs have traditionally been attributed to small
intestinal dysbiosis with increased folate production by some mem-
bers of the intestinal microbiota.11,26,27 However, there are no investi-
gations into this specifically in dogs with PLE.
To the authors' knowledge, the correlation between WSAVA histol-
ogy scores of duodenal biopsies and endoscopic scores of the duode-
num (but not between other histology and endoscopy scores) has not
been reported previously for dogs with PLE. This might help clinicians
to more confidently estimate severity of disease during endoscopy.
Severe endoscopic duodenal scores were associated with negative out-
come in a previous study,8 and with CIBDAI scores in another. The fact
that this was not true for the ileum might be because of the small num-
ber of dogs in which ileal biopsies were performed. Also, standardized
scoring of both endoscopy and histology findings specifically for the
ileum is not included in the WSAVA guidelines,20 even though the scor-
ing system used for duodenal biopsies has been previously validated
for ileal lesions.28,29 This study highlights the need for a more compre-
hensive histological assessment of the ileum.29
This study has the typical limitations of any retrospective study, in
that additional treatments and diets were not standardized, which could
haven skewed outcome measures. Clinical signs were not objectively
assessed using, for example, the CIBDAI or CCECAI scoring systems7,8;
there was no exact definition of what constituted an acceptable partial
or complete response to treatment, and revisits and follow-up times
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F IGURE 7 Kaplan-Meier survival plot of dogs with protein-losing
enteropathy (PLE) treated with prednisolone alone (group P) and
treated with prednisolone and a second-line immunosuppressant
(group S). Vertical lines indicate censored cases
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were not standardized. It is possible that the decision of adding an SLI in
individual dogs was also taken because of the presence of unacceptable
glucocorticoid adverse effects despite clinical or biochemical improve-
ment. It was up to the respective clinicians which SLI was chosen, even
though in the all but 1 case this was cyclosporine. We can also not fully
exclude that dogs with undetected neoplasia (especially small cell lym-
phoma) were erroneously included in this study, as immunohistochemis-
try was only performed in cases in which initial histology assessment
could not clearly differentiate inflammation from neoplasia.
This study did not investigate the effect of diet (alone or in combi-
nation with other treatments) on the progression or outcome of PLE
in dogs, and all dogs were fed a hypoallergenic/hydrolyzed diet rather
than a low fat diet. This could have influenced overall outcome, as
good response to low-fat diets alone has been reported.30,31
It is worth considering if cyclosporine is an adequate SLI in dogs
with PLE and whether it is an appropriate first choice once steroid
treatment alone (or diet) has been deemed insufficient. There are no
studies comparing the use of cyclosporine with another SLI in dogs
with PLE. Chlorambucil produced a better response to treatment and
outcome compared with azathioprine, but has not been directly com-
pared to cyclosporine.1 Depending on the SLI chosen, the decision to
omit SLI treatment can be an economic advantage for the client.
In addition, most drugs used as SLI can cause adverse effects, the
majority of which associated with the GI tract. Not only could this
lead to decreased compliance with drug administration or the inability
to administer oral drugs, it could also interfere with monitoring clinical
improvement and cause additional concern to dog owners.
In conclusion, this study should encourage veterinarians to con-
sider treating PLE with glucocorticoids alone, especially if dietary
management failed and financial concerns are present.
ACKNOWLEDGMENTS
The authors thank all clinicians and nurses working at the Hospital for
Small Animals in Edinburgh, Susan Campbell, Nicole Pitulia, and Mazdak
Salavati, who assisted with statistics. Parts of this paper were presented
as an oral abstract at the ECVIM congress 2018 in Rotterdam, the
Netherlands.
CONFLICT OF INTEREST DECLARATION
Authors declare no conflict of interest.
OFF-LABEL ANTIMICROBIAL DECLARATION
Authors declare no off-label use of antimicrobials.
INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE
(IACUC) OR OTHER APPROVAL DECLARATION
Authors declare no IACUC or other approval was needed.
HUMAN ETHICS APPROVAL DECLARATION
Authors declare human ethics approval was not needed for this study.
ORCID
Silke Salavati Schmitz https://orcid.org/0000-0003-1084-7013
REFERENCES
1. Dandrieux JRS, Noble PM, Scase TJ, Cripps PJ, German AJ. Comparison
of a chlorambucil-prednisolone combination with an azathioprine-
prednisolone combination for treatment of chronic enteropathy with
concurrent protein-losing enteropathy in dogs: 27 cases (2007–2010).
J Am Vet Med Assoc. 2013;242(12):1705-1714.
2. Peterson PB, Willard MD. Protein-losing enteropathies. Vet Clin North
Am Small Anim Pract. 2003;33(5):1061-1082.
3. Dossin O, Lavoué R. Protein-losing enteropathies in dogs. Vet Clin
North Am Small Anim Pract. 2011;41(2):399-418.
4. Flesjå K, Yri T. Protein-losing enteropathy in the Lundehund. J Small
Anim Pract. 1977;18(1):11-23.
5. Melville-Walker SW, Smith KC, Elwood CM. Protein-losing enteropa-
thy in a soft-coated wheaten terrier in the United Kingdom. Vet Rec.
2004;154(14):440-441.
6. Littman MP, Dambach DM, Vaden SL, Giger U. Familial protein-losing
enteropathy and protein-losing nephropathy in soft coated wheaten
terriers: 222 cases (1983-1997). J Vet Intern Med. 2000;14(1):68-80.
7. Jergens AE, Schreiner CA, Frank DE, et al. A scoring index for disease
activity in canine inflammatory bowel disease. J Vet Intern Med. 2003;
17(3):291-297.
8. Allenspach K, Wieland B, Gröne A, Gaschen F. Chronic enteropathies
in dogs: evaluation of risk factors for negative outcome. J Vet Intern
Med. 2007;21(4):700-708.
9. Craven M, Simpson JW, Ridyard AE, Chandler ML. Canine inflamma-
tory bowel disease: retrospective analysis of diagnosis and outcome
in 80 cases (1995-2002). J Small Anim Pract. 2004;45(7):336-342.
10. Simmerson SM, Armstrong PJ, Wünschmann A, Jessen CR, Crews LJ,
Washabau RJ. Clinical features, intestinal histopathology, and out-
come in protein-losing enteropathy in Yorkshire Terrier dogs. J Vet
Intern Med. 2014;28(2):331-337.
11. Equilino M, Théodoloz V, Gorgas D, et al. Evaluation of serum bio-
chemical marker concentrations and survival time in dogs with protein-
losing enteropathy. J Am Vet Med Assoc. 2015;246(1):91-99.
12. Gianella P, Lotti U, Bellino C, et al. Clinicopathologic and prognostic
factors in short- and long-term surviving dogs with protein-losing
enteropathy. Schweiz Arch Tierheilkd. 2017;159(3):163-169.
13. Nakashima K, Hiyoshi S, Ohno K, et al. Prognostic factors in dogs
with protein-losing enteropathy. Vet J. 2015;205(1):28-32.
14. Allenspach K, Rizzo J, Jergens AE, Chang YM. Hypovitaminosis D is
associated with negative outcome in dogs with protein losing enter-
opathy: a retrospective study of 43 cases. BMC Vet Res. 2017;13
(1):96.
15. Craven MD, Washabau RJ. Comparative pathophysiology and man-
agement of protein-losing enteropathy. J Vet Intern Med. 2019;33(2):
383-402.
16. Sutherland-Smith J, Penninck DG, Keating JH, Webster CRL. Ultraso-
nographic intestinal hyperechoic mucosal striations in dogs are asso-
ciated with lacteal dilation. Vet Radiol Ultrasound. 2007;48(1):51-57.
17. Gaschen L, Kircher P, Stüssi A, et al. Comparison of ultrasonographic
findings with clinical activity index (CIBDAI) and diagnosis in dogs
with chronic enteropathies. Vet Radiol Ultrasound. 2008;49(1):56-64.
8 SALAVATI SCHMITZ ET AL.
18. Yuki M, Sugimoto N, Takahashi K, et al. A case of protein-losing
enteropathy treated with methotrexate in a dog. J Vet Med Sci. 2006;
68(4):397-399.
19. Slovak JE, Wang C, Sun Y, et al. Development and validation of an
endoscopic activity score for canine inflammatory bowel disease. Vet
J. 2015;203(3):290-295.
20. Washabau RJ, Day MJ, Willard MD, et al. Endoscopic, biopsy, and his-
topathologic guidelines for the evaluation of gastrointestinal inflam-
mation in companion animals. J Vet Intern Med. 2010;24(1):10-26.
21. Day MJ, Bilzer T, Mansell J, et al. Histopathological standards for the
diagnosis of gastrointestinal inflammation in endoscopic biopsy sam-
ples from the dog and cat: a report from the World Small Animal Vet-
erinary Association Gastrointestinal Standardization Group. J Comp
Pathol. 2008 Feb;138(Suppl 1):S1-S43.
22. Leib MS, Larson MM, Grant DC, et al. Diagnostic utility of abdominal
ultrasonography in dogs with chronic diarrhea. J Vet Intern Med.
2012;26(6):1288-1294.
23. Shane B. Folate and vitamin B12 metabolism: overview and interac-
tion with riboflavin, vitamin B6, and polymorphisms. Food Nutr Bull.
2008;29(2 Suppl):S5-S16. discussion S17-9.
24. Carmel R, Melnyk S, James SJ. Cobalamin deficiency with and without
neurologic abnormalities: differences in homocysteine and methio-
nine metabolism: presented in preliminary form at the 44th Annual
Meeting of the American Society of Hematology, Philadelphia, PA,
December 7, 2002. Blood. 2003;101(8):3302-3308.
25. Stanley E, Appleman E, Schlag A, Siegel A. Relationship between
cobalamin and folate deficiencies and anemia in dogs. J Vet Intern
Med. 2019;33(1):106-113.
26. Ruaux CG, Steiner JM, Williams DA. Protein-losing enteropathy in
dogs is associated with decreased fecal proteolytic activity. Vet Clin
Pathol. 2004;33(1):20-22.
27. Ruaux CG. Cobalamin in companion animals: diagnostic marker, defi-
ciency states and therapeutic implications. Vet J. 2013;196(2):145-152.
28. Allenspach KA, Mochel JP, Du Y, et al. Correlating gastrointestinal
histopathologic changes to clinical disease activity in dogs with idio-
pathic inflammatory bowel disease. Vet Pathol. 2019;56(3):435-443.
29. Procoli F, Mõtsküla PF, Keyte SV, Priestnall S, Allenspach K. Compari-
son of histopathologic findings in duodenal and ileal endoscopic biop-
sies in dogs with chronic small intestinal enteropathies. J Vet Intern
Med. 2013 Mar;27(2):268-274.
30. Okanishi H, Yoshioka R, Kagawa Y, Watari T. The clinical efficacy of
dietary fat restriction in treatment of dogs with intestinal
lymphangiectasia. J Vet Intern Med. 2014;28(3):809-817.
31. Rudinsky AJ, Howard JP, Bishop MA, Sherding RG, Parker VJ, Gilor C.
Dietary management of presumptive protein-losing enteropathy in
Yorkshire Terriers. J Small Anim Pract. 2017;58(2):103-108.
SUPPORTING INFORMATION
Additional supporting information may be found online in the
Supporting Information section at the end of this article.
How to cite this article: Salavati Schmitz S, Gow A,
Bommer N, Morrison L, Mellanby R. Diagnostic features,
treatment, and outcome of dogs with inflammatory protein-
losing enteropathy. J Vet Intern Med. 2019;1–9. https://doi.
org/10.1111/jvim.15571
SALAVATI SCHMITZ ET AL. 9
